Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.

2.

Study to Compare the Effect of Different Registration Methods on Patient Setup Uncertainties in Cone-beam Computed Tomography during Volumetric Modulated Arc Therapy for Breast Cancer Patients.

Mohandass P, Khanna D, Kumar TM, Thiyagaraj T, Saravanan C, Bhalla NK, Puri A.

J Med Phys. 2018 Oct-Dec;43(4):207-213. doi: 10.4103/jmp.JMP_67_18.

3.

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.

Arthritis Res Ther. 2019 Jan 7;21(1):8. doi: 10.1186/s13075-018-1788-4.

4.

Generation of a core set of items to develop classification criteria for Scleroderma renal crisis using consensus methodology.

Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group.

Arthritis Rheumatol. 2019 Jan 7. doi: 10.1002/art.40809. [Epub ahead of print]

PMID:
30614663
5.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Jan 3. doi: 10.1093/qjmed/hcy272. [Epub ahead of print] No abstract available.

PMID:
30605544
6.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Jan 3. doi: 10.1002/art.40769. [Epub ahead of print] No abstract available.

PMID:
30604506
7.

Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.

Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, Metzger AL, Khanna D.

J Clin Rheumatol. 2018 Dec 20. doi: 10.1097/RHU.0000000000000971. [Epub ahead of print]

PMID:
30585996
8.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2018 Dec 15. pii: jrheum.180478. doi: 10.3899/jrheum.180478. [Epub ahead of print]

PMID:
30554156
9.

Diagnosis of pulmonary hypertension.

Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A.

Eur Respir J. 2018 Dec 13. pii: 1801904. doi: 10.1183/13993003.01904-2018. [Epub ahead of print]

10.

Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.

McMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, Matucci-Cerinic M, Smith V, Melsens K, Proudman S, Zhang J, Mendoza F, Woods M, Khanna D.

J Rheumatol. 2019 Jan;46(1):78-84. doi: 10.3899/jrheum.180004. Epub 2018 Nov 15.

PMID:
30442827
11.

Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D.

Semin Arthritis Rheum. 2018 Oct 14. pii: S0049-0172(18)30446-3. doi: 10.1016/j.semarthrit.2018.10.010. [Epub ahead of print]

PMID:
30415942
12.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.

PMID:
30409830
13.

Ensemble Technique for Prediction of T-cell Mycobacterium tuberculosis Epitopes.

Khanna D, Rana PS.

Interdiscip Sci. 2018 Nov 7. doi: 10.1007/s12539-018-0309-0. [Epub ahead of print]

PMID:
30406342
14.

Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.

Khanna D, Jahreis A, Lin CJF.

Ann Rheum Dis. 2018 Oct 23. pii: annrheumdis-2018-214477. doi: 10.1136/annrheumdis-2018-214477. [Epub ahead of print] No abstract available.

PMID:
30352886
15.

Reply.

Bernstein EJ, Khanna D, Lederer DJ.

Arthritis Rheumatol. 2018 Oct 22. doi: 10.1002/art.40762. [Epub ahead of print] No abstract available.

PMID:
30346112
16.

Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans.

Almario CV, Ballal ML, Chey WD, Nordstrom C, Khanna D, Spiegel BMR.

Am J Gastroenterol. 2018 Nov;113(11):1701-1710. doi: 10.1038/s41395-018-0256-8. Epub 2018 Oct 15.

PMID:
30323268
17.

Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.

Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):146-149. Epub 2018 Sep 30.

PMID:
30277862
18.

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.

Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD.

J Rheumatol. 2018 Oct 1. pii: jrheum.180018. doi: 10.3899/jrheum.180018. [Epub ahead of print]

PMID:
30275260
19.

Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP.

Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.

PMID:
30265153
20.

Validation of a Software Upgrade in a Monte Carlo Treatment Planning System by Comparison of Plans in Different Versions.

Mohandass P, Khanna D, Manigandan D, Bhalla NK, Puri A.

J Med Phys. 2018 Apr-Jun;43(2):93-99. doi: 10.4103/jmp.JMP_7_18.

21.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

22.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2018 Jun 8. doi: 10.1093/rheumatology/key151. [Epub ahead of print]

PMID:
29893938
23.

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R.

Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.

PMID:
29858547
24.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

25.

Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.

He Y, Tsou PS, Khanna D, Sawalha AH.

Ann Rheum Dis. 2018 Aug;77(8):1208-1218. doi: 10.1136/annrheumdis-2018-213022. Epub 2018 May 14.

PMID:
29760157
26.

A Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis.

Khanna D, Serrano J, Berrocal VJ, Silver RM, Cuencas P, Newbill SL, Battyany J, Maxwell C, Alore M, Dyas L, Riggs R, Connolly K, Kellner S, Fisher JJ, Bush E, Sachdeva A, Evnin L, Raisch DW, Poole JL.

Arthritis Care Res (Hoboken). 2018 May 9. doi: 10.1002/acr.23595. [Epub ahead of print]

PMID:
29741230
27.

Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1634-1643. doi: 10.1002/art.40547. Epub 2017 Nov 6.

PMID:
29732731
28.

Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans.

Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM.

Arthritis Rheumatol. 2018 Oct;70(10):1654-1660. doi: 10.1002/art.40541. Epub 2018 Aug 29.

PMID:
29732714
29.

pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE, Khanna D, Singh RR.

JCI Insight. 2018 May 3;3(9). pii: 98380. doi: 10.1172/jci.insight.98380. [Epub ahead of print]

30.

Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.

Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.

Semin Arthritis Rheum. 2018 Apr 4. pii: S0049-0172(18)30013-1. doi: 10.1016/j.semarthrit.2018.03.019. [Epub ahead of print] Review.

PMID:
29706243
31.

Monoclonal Gammopathy-Associated Scleromyxedema Presenting as Leonine Facies.

Park AY, Lowe L, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1694. doi: 10.1002/art.40530. No abstract available.

PMID:
29676525
32.

The patient experience of Raynaud's phenomenon in systemic sclerosis.

Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D.

Rheumatology (Oxford). 2019 Jan 1;58(1):18-26. doi: 10.1093/rheumatology/key026.

PMID:
29538754
33.

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1373-1384. doi: 10.1002/acr.23475. Epub 2018 Aug 16.

PMID:
29473715
34.

Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists.

Bernstein EJ, Khanna D, Lederer DJ.

Arthritis Rheumatol. 2018 Jun;70(6):971-972. doi: 10.1002/art.40441. Epub 2018 Apr 24. No abstract available.

PMID:
29426066
35.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

36.

Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Morgan ND, Shah AA, Mayes MD, Domsic RT, Medsger TA Jr, Steen VD, Varga J, Carns M, Ramos PS, Silver RM, Schiopu E, Khanna D, Hsu V, Gordon JK, Gladue H, Saketkoo LA, Criswell LA, Derk CT, Trojanowski MA, Shanmugam VK, Chung L, Valenzuela A, Jan R, Goldberg A, Remmers EF, Kastner DL, Wigley FM, Gourh P, Boin F.

Medicine (Baltimore). 2017 Dec;96(51):e8980. doi: 10.1097/MD.0000000000008980.

37.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.

PMID:
29381834
38.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

39.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

40.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2017 Nov 3. doi: 10.1164/rccm.201709-1845OC. [Epub ahead of print]

PMID:
29099620
41.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

42.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

43.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
44.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

45.

Assessment of skin involvement in systemic sclerosis.

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. Review.

46.

Points to consider in renal involvement in systemic sclerosis.

Galluccio F, Müller-Ladner U, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Review.

47.

Points to consider for skin ulcers in systemic sclerosis.

Galluccio F, Allanore Y, Czirjak L, Furst DE, Khanna D, Matucci-Cerinic M.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v67-v71. doi: 10.1093/rheumatology/kex200. Review.

48.

Points to consider-Raynaud's phenomenon in systemic sclerosis.

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v45-v48. doi: 10.1093/rheumatology/kex199. Review.

49.

Points to consider when doing a trial primarily involving the heart.

Allanore Y, Distler O, Walker UA, Khanna D, Furst DE, Meune C.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v12-v16. doi: 10.1093/rheumatology/kex198. Review.

50.

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Humbert M, Singh M, Furst DE, Khanna D, Seibold JR.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v33-v37. doi: 10.1093/rheumatology/kex197. Review.

Supplemental Content

Loading ...
Support Center